Correction: Association between the metabolic score for insulin resistance trajectory and new-onset metabolic syndrome: a retrospective cohort study based on health check-up data in China

Correction: Lipids in Health and Disease 24, 271 (2025)

https://doi.org/10.1186/s12944-025–02690-8

Following publication of the original article [1], the authors reported a typesetting mistake. Tables 1, 2 and 3 below were missing in the main text.

Table 1.

Baseline demographic and clinical data according to METS-IR trajectory group

Indicators	Total N = 3750	Low-stability Group N = 3316	High-stability Group N = 434	Z/χ²	P
Number of cases (Male/Female)	1504/2246	1447/1869	57/377	148.65	< 0.001
Age [years, M (Q1,Q3)]	46.00 (35.00, 55.00)	46.00 (35.00, 56.00)	42.00 (35.00, 54.00)	−2.49	0.013
Avg METS-IR [M (Q1, Q3)]	33.56 (29.92, 37.25)	32.74 (29.44, 35.96)	41.93 (40.71, 43.78)	−33.62	< 0.001
WC [cm, M (Q1, Q3)]	82.00 (76.00, 88.00)	81.00 (75.00, 87.00)	90.00 (87.00, 96.00)	−22.71	< 0.001
SBP [mmHg, M (Q1, Q3)]	119.00 (109.00, 130.00)	118.00 (109.00, 130.00)	120.00 (112.00, 129.00)	−2.07	0.038
DBP [mmHg, M (Q1, Q3)]	73.00 (66.00, 80.00)	72.00 (66.00, 80.00)	75.00 (70.00, 81.25)	−5.33	< 0.001
BMI [kg/m², M (Q1, Q3)]	23.74 (21.85, 25.53)	23.34 (21.63, 24.93)	27.52 (25.97, 29.04)	−28.08	< 0.001
ALT [U/L, M (Q1, Q3)]	16.00 (12.00, 23.00)	16.00 (12.00, 22.00)	21.00 (16.00, 30.00)	−11.91	< 0.001
AST [U/L, M (Q1, Q3)]	20.00 (17.00, 23.00)	19.00 (17.00, 23.00)	21.00 (18.00, 25.00)	−4.85	< 0.001
GGT [U/L, M (Q1, Q3)]	17.00 (12.00, 26.00)	17.00 (12.00, 24.00)	26.00 (18.00, 37.00)	−13.33	< 0.001
Scr [µmol/L, M (Q1, Q3)]	73.00 (62.00, 83.00)	71.00 (61.00, 82.00)	79.00 (69.75, 86.00)	−8.70	< 0.001
SUA [µmol/L, M (Q1, Q3)]	314.00 (260.00, 371.00)	306.00 (254.00, 361.00)	374.50 (318.00, 420.00)	−14.69	< 0.001
eGFR [ml/ (min*1.73 m², M (Q1, Q3)]	101.49 (90.37, 110.64)	101.58 (90.21, 110.69)	100.97 (91.77, 109.90)	−0.02	0.986
TC [mmol/L, M (Q1, Q3)]	4.55 (4.01, 5.14)	4.56 (4.01, 5.14)	4.52 (4.00, 5.12)	−0.62	0.537
TG [mmol/L, M (Q1, Q3)]	1.07 (0.81, 1.49)	1.04 (0.78, 1.43)	1.43 (1.08, 1.99)	−13.28	< 0.001
HDL-C [mmol/L, M (Q1, Q3)]	1.40 (1.21, 1.64)	1.44 (1.24, 1.67)	1.18 (1.04, 1.35)	−17.78	< 0.001
LDL-C [mmol/L, M (Q1, Q3)]	2.77 (2.26, 3.28)	2.75 (2.25, 3.26)	2.83 (2.36, 3.35)	−2.43	0.015
FPG [mmol/L, M (Q1, Q3)]	5.15 (4.86, 5.49)	5.14 (4.85, 5.48)	5.25 (4.96, 5.60)	−4.35	< 0.001
HbA1c [%, M (Q1, Q3)]	5.53 (5.37, 5.75)	5.52 (5.37, 5.75)	5.57 (5.40, 5.60)	−1.81	0.070
Smoking, n (%)	1352 (36.05)	1109 (33.44)	243 (55.99)	84.62	< 0.001
Drinking, n (%)	1589 (42.37)	1362 (41.07)	227 (52.30)	19.82	< 0.001
Hypertension, n (%)	341 (9.09)	302 (9.11)	39 (8.99)	0.01	0.510
Diabetes, n (%)	106 (2.83)	97 (2.93)	9 (2.07)	1.01	0.200
Hyperlipidemia, n (%)	140 (3.73)	123 (3.71)	17 (3.92)	0.05	0.455
Antihypertensive medication, n (%)	139 (3.71)	118 (3.56)	21 (4.84)	1.76	0.119
Antidiabetic drug, n (%)	49 (1.31)	41 (1.24)	8 (0.02)	1.10	0.200
Lipid-lowering agents, n (%)	72 (1.92)	61 (1.84)	11 (2.53)	0.98	0.205
MetS, n (%)	430 (11.47)	276 (8.32)	154 (35.48)	278.87	< 0.001

Abbreviations: Avg METS-IR Average metabolic syndrome-insulin resistance, WC Waist circumference; SBP: Systolic blood pressure, DBP Diastolic blood pressure, BMI Body mass index, ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyl transferase, Scr Serum creatinine, SUA Serum uric acid, eGFR Estimated glomerular filtration rate, TC Total cholesterol, TG Triglyceride, HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol, FPG Fasting plasma glucose, HbA1c Glycated hemoglobin

Table 2.

Risk models for the incidence of metabolic syndrome according to MetS-IR trajectory group

	Total Population		Age < 45 years		Age ≥ 45 years
	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P
Model 1
Low-stability Group	1.000		1.000		1.000
High-stability Group	6.058 (4.803, 7.640)	< 0.001	9.165 (6.557, 12.810)	< 0.001	4.365 (3.118, 6.110)	< 0.001
Model 2
Low-stability Group	1.000		1.000		1.000
High-stability Group	5.042 (3.961, 6.416)	< 0.001	6.832 (4.825, 9.674)	< 0.001	3.811 (2.695, 5.389)	< 0.001
Model 3
Low-stability Group	1.000		1.000		1.000
High-stability Group	5.247 (4.111, 6.696)	< 0.001	6.868 (4.842, 9.740)	< 0.001	4.037 (2.839, 5.741)	< 0.001
Model 4
Low-stability Group	1.000		1.000		1.000
High-stability Group	4.770 (3.714, 6.126)	< 0.001	6.202 (4.312, 8.921)	< 0.001	3.891 (2.720, 5.566)	< 0.001

Model 1, no adjustment; model 2, adjusted for sex and age (only for the total population); model 3, adjusted for sex, age (only for the total population) with addition of hypertension and diabetes status; model 4, based on model 3 with addition of gamma-glutamyl transferase, low-density lipoprotein cholesterol, serum uric acid

Table 3.

Cox proportional hazards regression model 4 for the risk of new-onset metabolic syndrome

Variables	β	Sx̄	Wald χ²	P	HR (95%CI)
METS-IR trajectory groups (Q1)	1.562	0.128	149.652	< 0.001	4.770 (3.714,6.126)
Gender (Male)	0.768	0.158	23.519	< 0.001	2.156 (1.581,2.941)
Age (years)	0.009	0.004	4.623	0.032	1.009 (1.001,1.017)
Hypertension (no hypertension)	0.618	0.164	14.210	< 0.001	1.855 (1.345,2.558)
Diabetes (no diabetes)	1.316	0.242	29.632	< 0.001	3.727 (2.321,5.986)
GGT (U/L)	0.009	0.002	15.312	< 0.001	1.009 (1.004,1.013)
LDL-C (mmol/L)	0.317	0.069	21.114	< 0.001	1.373 (1.199,1.572)
SUA (µmol/L)	0.002	0.001	6.422	0.011	1.002 (1.000,1.004)

Model 4: adjusted for sex, age, hypertension and diabetes status, GGT, SUA, LDL-C. IR trajectory group and gender are categorical variables, and the reference groups are marked after the variables. Abbreviations: GGT Gamma-glutamyl transferase, HR Hazard ratio, METS-IR Metabolic Score for Insulin Resistance, SUA Serum uric acid, LDL-C Low-density lipoprotein cholesterol

The original article [1] has been corrected.